As boosters are authorized for all three COVID-19 shots available in the US, the ability to swap out vaccine types looks to be a boon to the immune system.
Academic rigor, journalistic flair
Articles on Moderna
Displaying 21 - 40 of 66 articles
There are very few situations where someone can’t have a COVID vaccine for medical reasons.
A medical student answers questions he gets asked at a COVID-19 vaccine clinic: Efficacy versus real-world effectiveness, immune response and how the mRNA vaccines compare to vaccines already in wide use.
University of Canberra Professorial Fellow Michelle Grattan and University of Canberra Associate Professor Caroline Fisher discuss the week in politics.
Doses of the Moderna vaccine will be available in Australia from mid-September. So if you’re in an eligible group you could be offered either Pfizer or Moderna. Here’s how they compare.
The Moderna vaccine has been provisionally approved by the Therapeutic Goods Administration for use in Australia, with one million doses due in the second half of September, which will go to pharmacies.
As Los Angeles County again mandates masking indoors – even for the fully vaccinated – local health officials in the U.S. are closely eyeing their own COVID-19 vaccination and infection rates.
As many teens and adults in the US restart their social lives, parents of children under the age of 12 wonder when their kids will also be able to experience the freedom that comes with vaccination.
If Big Pharma wants to achieve the ultimate image makeover, it must capitalize on the current public good will about its COVID-19 vaccines by prioritizing socially responsible practices.
This myth is still circulating online. Here’s why the chance of this happening is next to zero.
Even if we came up with a definition of what makes the “best” vaccine, we don’t have the luxury of choice, when vaccines are in short supply.
A vaccine expert breaks down everything you need to know about Australia’s newest COVID-19 vaccine candidate.
This week’s budget assumes all Australians will have the chance to be fully vaccinated by the end of the year. It’s ambitious but possible.
Canadian public health organizations have run into a serious communication problem about the AstraZeneca vaccine. Crisis management and communication theories explain what’s gone wrong.
The anticipated arrival of two new vaccines can boost the morale of those worried about the wait for their dose.
So far, most vaccines in the US are mRNA vaccines. These represent a new technology and are likely to take over the vaccine world. But how do they work? What are their weaknesses? Five experts explain.
The coronavirus pandemic has driven a lot of scientific progress in the past year. But just as some of the social changes are likely here to stay, so are some medical innovations.
The Johnson & Johnson vaccine is different from the Moderna and Pfizer vaccines in a few important ways that could make it a huge help to global vaccination efforts.
With the vaccines now being administered at sites around the US, it is important to address misinformation surrounding the effort.
The arrival of COVID-19 vaccines has raised hope for an end to the pandemic. Hopefully that’s true, but there are variables. Here are some factors that could affect the success of the vaccine rollout.
Top contributors
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Professor of Medicine, University of Virginia
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Professor of Microbiology, School of Medicine, University of Washington
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
-
Joel Lexchin is a Friend of The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Assistant Professor, School of Professional Communication, Toronto Metropolitan University
-
Paediatrician at the Royal Childrens Hospital and Associate Professor and Clinician Scientist, University of Melbourne and MCRI, Murdoch Children's Research Institute
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor of Law, Villanova School of Law
-
Professorial Fellow, University of Canberra
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Associate Professor of Bioethics, University of Portsmouth
-
Associate Professor of Epidemiology, University of San Francisco
-
Professor of Epidemiology, Population Interventions Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne
